1982
DOI: 10.1016/0378-5122(82)90022-6
|View full text |Cite
|
Sign up to set email alerts
|

An intrauterine progesterone contraceptive system (52 mg) used in pre- and peri-menopausal patients with endometrial hyperplasia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
2
0
2

Year Published

1984
1984
2010
2010

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 11 publications
(4 citation statements)
references
References 15 publications
0
2
0
2
Order By: Relevance
“…Papers were included if they reported histological follow up of women diagnosed with endometrial hyperplasia and treated with a LNG‐IUS. After excluding one paper 15 which appeared to be an earlier report of a study that was later reported in full, 7 one that was second report 9 from the same study population 16 and one that reported on the effects of Progestasert®, a 65‐µg releasing device no longer available, and used unspecified criteria for histologic diagnosis, 17 we identified nine studies 7,8,10–14,16,18 and three case reports 19–21 that met the criteria for inclusion. There were no randomised controlled trials of a LNG‐IUS used for the treatment of endometrial hyperplasia.…”
Section: Methodsmentioning
confidence: 99%
“…Papers were included if they reported histological follow up of women diagnosed with endometrial hyperplasia and treated with a LNG‐IUS. After excluding one paper 15 which appeared to be an earlier report of a study that was later reported in full, 7 one that was second report 9 from the same study population 16 and one that reported on the effects of Progestasert®, a 65‐µg releasing device no longer available, and used unspecified criteria for histologic diagnosis, 17 we identified nine studies 7,8,10–14,16,18 and three case reports 19–21 that met the criteria for inclusion. There were no randomised controlled trials of a LNG‐IUS used for the treatment of endometrial hyperplasia.…”
Section: Methodsmentioning
confidence: 99%
“…Progestogens can be delivered systemically, either alone or in combination with estrogen (in the form of the combined oral contraceptive pill or hormone replacement therapy), or locally in the form of the levonorgestrel intrauterine device (Mirena ® , Schering Health, Burgess Hill, West Sussex, UK). Both systemic and local administration of progestogens has shown a 75–90% 7 and 90–100% 31,32 conversion rate of nonatypical endometrial hyperplasia to normal endometrium, respectively.…”
Section: Treatmentmentioning
confidence: 99%
“…Ακόμη, για την αντιμετώπιση των υπερπλαστικών βλαβών του ενδο μητρίου, έχει περιγραφεί η τοποθέτηση ενδομήτριων σπειραμάτων που φέρουν προγεστερινοειδή (λεβονογεστρέλη) και τα απελευθερώνουν σταδιακά (Volpe et al 1982, Perino et al 1987, Scarselli et al 1988. Ενώ α σκούν τοπική δράση στο ενδομήτριο, η χρήση τους δε συνοδεύεται από τις συστηματικές επιπτώσεις των προγεστερινοειδών (Volpe et al 1982). Τέ λος, οι Affinito και συν.…”
Section: γ σχήματα θεραπείαςunclassified
“…Ενθαρρυντικά είναι τα αποτελέσματα από την τοποθέτηση ενδομή τριων σπειραμάτων με προγεστερινοειδή. Υποστροφή της βλάβης ανεξάρ-τητα από την ιστολογική τους εικόνα παρατηρείται στο σύνολο σχεδόν των περιπτώσεων (Volpe et al 1982, Perino et al 1987, Scarselli et al 1988.…”
Section: ιδ αποτελέσματαunclassified